Washington, United States
Altoida, Inc. is reshaping the field of neurological diagnostics by pioneering digital biomarkers through the integration of augmented reality and machine learning. Established in 2016 and headquartered in the United States, this venture-backed startup focuses on providing an objective evaluation of cognitive health, particularly for conditions like Alzheimer’s Disease.
With over two decades of scientific research fuelling its evidence-based platform, Altoida utilizes state-of-the-art technology to enhance the monitoring of disease progression and response to treatment. Its platform is validated by various peer-reviewed publications in respected journals, such as Nature Digital Medicine.
The company operates at the intersection of several burgeoning industries: AI, Digital Health, Health Care, Medical Devices, and VR/AR. Their last funding round was a $14.00M Series A on 30 March 2022, with investments from Fyrfly Venture Partners, VI Partners, and others, underlining strong investor confidence.
